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Introduction {#emmm201505801-sec-0001}
============

The incidence of obesity is at an epidemic level worldwide and is a strong risk factor for a number of ageing‐related diseases including type 2 diabetes (T2D), cardiovascular disease and the metabolic syndrome, and thus poses a tremendous burden on quality of life and health care systems worldwide (Popkin *et al*, [2012](#emmm201505801-bib-0065){ref-type="ref"}). Thus, there is a desperate need for more effective strategies to curtail this trend, whether through prescription of behavioural or pharmacological treatments.

A hallmark of obesity‐driven T2D is insulin resistance (Bjorntorp, [1997](#emmm201505801-bib-0010){ref-type="ref"}), and thus, much effort is placed into treatments that promote "insulin sensitisation" (Connor *et al*, [2015](#emmm201505801-bib-0019){ref-type="ref"}). While there is no doubt that insulin is an important mediator of metabolic control in the prandial state (Boucher *et al*, [2014](#emmm201505801-bib-0012){ref-type="ref"}), insulin resistance likely represents a physiological feedback mechanism to actually retard the development of obesity‐driven complications (Hoehn *et al*, [2009](#emmm201505801-bib-0034){ref-type="ref"}), prompting speculation that "insulin sensitisation" may be a flawed strategy (Connor *et al*, [2015](#emmm201505801-bib-0019){ref-type="ref"}). This is exemplified by studies demonstrating that tissue‐restricted loss of function of key insulin signalling nodes actually extends health span of mice (Bluher *et al*, [2003](#emmm201505801-bib-0011){ref-type="ref"}; Taguchi *et al*, [2007](#emmm201505801-bib-0074){ref-type="ref"}) and that insulin *per se* can promote the progression of obesity‐related metabolic dysfunction (Mehran *et al* [2012](#emmm201505801-bib-0801){ref-type="ref"}). Thus, alternative strategies are warranted, such as mild and intermittent activation of stress‐responsive pathways that are pro‐adaptive (Ristow & Zarse, [2010](#emmm201505801-bib-0066){ref-type="ref"}; Kolb & Eizirik, [2012](#emmm201505801-bib-0043){ref-type="ref"}).

One such strategy could be intermittent nutrient withdrawal. Nutrient withdrawal (i.e. fasting) is protective against modern chronic diseases such as cancer, neurodegeneration, cardiovascular disease and diabetes (Longo & Mattson, [2014](#emmm201505801-bib-0053){ref-type="ref"}). In particular, a recent study demonstrated that across multiple species including humans, a periodic diet that mimics fasting had a positive effect on lifespan and biomarkers of cognitive, immune and cardiometabolic function (Brandhorst *et al*, [2015](#emmm201505801-bib-0013){ref-type="ref"}). Concerning metabolic function, although it is known that there are several systemic adaptive changes in metabolism with nutrient withdrawal (Cahill, [2006](#emmm201505801-bib-0014){ref-type="ref"}), little is known of the tissue‐specific molecular mechanisms by which fasting can improve organismal metabolic control and retard the development of metabolic disease (Longo & Mattson, [2014](#emmm201505801-bib-0053){ref-type="ref"}).

Although it is well accepted that the liver is a pivotal organ contributing to metabolic control (van den Berghe, [1991](#emmm201505801-bib-0009){ref-type="ref"}), whether the liver actually contributes in many aspects of metabolic control during fasting, and molecular mechanisms therein, remains largely unknown. It is known that the liver is the primary site of glucose production and can provide alternate substrates such as ketone bodies under fasting conditions (van den Berghe, [1991](#emmm201505801-bib-0009){ref-type="ref"}). Interestingly, the liver transcriptome starvation response correlates with lifespan prolonging processes (Bauer *et al*, [2004](#emmm201505801-bib-0008){ref-type="ref"}) and it is hypothesised that resistance to stress is an important determinant of survival and longevity (Calabrese *et al*, [2011](#emmm201505801-bib-0016){ref-type="ref"}). Hence, one strategy to uncover the molecular mechanisms contributing to metabolic dysfunction could be to dissect the liver transcriptome to uncover select genes which are aberrantly regulated during fasting. To this end, our studies here identify a member of the "growth arrest and DNA damage‐inducible" (GADD45) gene family, namely GADD45β, as one such gene. Importantly, there are no studies that have systematically examined the role of GADD45β in metabolic function *in vivo*, and here, we demonstrate that liver GADD45β acutely regulates fatty acid handling under fasting stress, ultimately coordinating proper metabolic function under conditions of chronic nutrient oversupply.

Results {#emmm201505801-sec-0002}
=======

An altered lipid profile in mouse models of metabolic dysfunction is most pronounced in the fasted state {#emmm201505801-sec-0003}
--------------------------------------------------------------------------------------------------------

To examine the molecular bases of metabolic (dys)regulation during fasted and fed states, we required suitable mouse models. To this end, we examined mouse models of obesity (Kanasaki & Koya, [2011](#emmm201505801-bib-0037){ref-type="ref"}) including the obese/diabetic *db*/*db* mouse (Figs [1](#emmm201505801-fig-0001){ref-type="fig"}A--E and [EV1](#emmm201505801-fig-0001ev){ref-type="fig"}A--D), pre‐diabetic young New Zealand Obese mice (Figs [1](#emmm201505801-fig-0001){ref-type="fig"}F--N and [EV1](#emmm201505801-fig-0001ev){ref-type="fig"}E--H) and aged mice (Figs [1](#emmm201505801-fig-0001){ref-type="fig"}K--O and [EV1](#emmm201505801-fig-0001ev){ref-type="fig"}I--L). In particular, we subjected these mouse models to a fasting‐refeeding regimen and could demonstrate heightened blood glucose (BG; Fig [EV1](#emmm201505801-fig-0001ev){ref-type="fig"}A, E and I) most prominent in the fed and but also in the fasted state. In contrast, although there was evidence of higher serum non‐esterified fatty acids (NEFA; Fig [1](#emmm201505801-fig-0001){ref-type="fig"}A, F and K) in the fed state, surprisingly these levels were lower in models of metabolic dysfunction in the fasted state. This pattern was also reflected in the level of triglycerides (TG; Fig [1](#emmm201505801-fig-0001){ref-type="fig"}B, G and L), ketone bodies (KB; Fig [1](#emmm201505801-fig-0001){ref-type="fig"}G, H and M) as well as medium‐chain (MCAC; Fig [1](#emmm201505801-fig-0001){ref-type="fig"}D, I and N) and long‐chain (LCAC; Fig [1](#emmm201505801-fig-0001){ref-type="fig"}E, J and O) acylcarnitines, with only mild differences in free‐ (Fig [EV1](#emmm201505801-fig-0001ev){ref-type="fig"}B, F and J), acyl‐ (Fig [EV1](#emmm201505801-fig-0001ev){ref-type="fig"}C, G and K) and short‐chain (SCAC; Fig [EV1](#emmm201505801-fig-0001ev){ref-type="fig"}D, H and L) acylcarnitines.

![The dysregulated lipid metabolic phenotype of mouse models of metabolic dysfunction is most pronounced in the fasted state\
A--OMale 12‐weeks‐old wild‐type (WT; C57Bl/6J) or obese/diabetic monogenic (*db*/*db*;BKS.Cg‐m^+/+^ Lepr DB/J; *n* = 4/group, A--E), New Zealand Black (NZB) and polygenic obese/pre‐diabetic New Zealand Obese (NZO;*n* = 4/group; F--J), as well as young (i.e. 3 months) and aged (i.e. 22 months; *n* = 5/group; K--O), mice were fed *ad libitum* (fed) or fasted for 24 h (fasted). Serum non‐esterified fatty acids (A, F, K), triglycerides (B, G, L) and ketone bodies (C, H, M) were measured. In addition, serum acylcarnitine profiling was conducted and medium‐chain (D, I, N) and long‐chain (E, J, O) acylcarnitine concentrations are shown.P--SIn another cohort of mice, *ex vivo* long‐chain fatty acid (LCFA) metabolism, including uptake (P), oxidation (Q) and non‐oxidative LCFA disposal (NOFAD; R), in precision‐cut liver slices from fed and fasted WT and db/db mice (*n* = 3/group; 4 slices per mouse), were determined. In addition, in slices from fasted mice, glucose output was determined in the presence of incubation with NEFA (BSA‐NEFA) or vehicle (BSA) (S).Data information: Data are mean ± SEM. Effect of genotype/age, \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001. Effect of nutritional state: ^\#^ *P* \< 0.05, ^\#\#^ *P* \< 0.01, ^\#\#\#^ *P* \< 0.001. The statistical test used and respective *P*‐value outputs can be found in [Appendix Table S1](#emmm201505801-sup-0001){ref-type="supplementary-material"}.](EMMM-8-654-g002){#emmm201505801-fig-0001}

![The dysregulated lipid metabolic phenotype of mouse models of metabolic dysfunction is most pronounced in the fasted state\
A--LMale 12‐weeks‐old wild‐type (WT; C57Bl/6J) or obese/diabetic monogenic (*db*/*db*;BKS.Cg‐m^+/+^ Lepr DB/J; *n* = 4/group, A--D), New Zealand Black (NZB) and polygenic obese/pre‐diabetic New Zealand Obese (NZO;*n* = 4/group; E--H), as well as young (i.e. 3 months) and aged (i.e.22 months; *n* = 5/group; I--L), mice were fed *ad libitum* (fed) or fasted for 24 h (fasted). Blood glucose (BG, A, E, I) and serum acylcarnitine species including free carnitine (C0; B, F, J), acylcarnitine (C2; C, G, K) and short‐chain acylcarnitines (SCAC; D, H, L) were measured. Data are mean ± SEM. *n* = 4/group. Effect of genotype, \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001. Effect of nutritional state: ^\#^ *P* \< 0.05, ^\#\#^ *P* \< 0.01, ^\#\#\#^ *P* \< 0.001. The statistical test used and respective *P*‐value outputs can be found in [Appendix Table S1](#emmm201505801-sup-0001){ref-type="supplementary-material"}.](EMMM-8-654-g003){#emmm201505801-fig-0001ev}

We then examined liver‐specific metabolic control in a separate cohort using *ex vivo* liver metabolic tracing. In particular, long‐chain fatty acid (LCFA) uptake was higher in the fasted state, and this was exacerbated in *db*/*db* mice (Fig [1](#emmm201505801-fig-0001){ref-type="fig"}P). The higher fasting LCFA uptake in WT mice was largely explained by higher LCFA oxidation (Fig [1](#emmm201505801-fig-0001){ref-type="fig"}Q). However, in the *db*/*db* mice, the heightened LCFA oxidation could not account for the higher uptake rate, meaning that non‐oxidative LCFA disposal was enhanced. We examined incorporation into lipids but this was unchanged (data not shown). As fatty acids can indirectly affect hepatic glucose production (Ross *et al*, [1967](#emmm201505801-bib-0068){ref-type="ref"}), we examined liver glucose output, and indeed, it was higher in *db*/*db* mice, particularly in the presence of exogenous NEFA ([Appendix Fig S1](#emmm201505801-sup-0001){ref-type="supplementary-material"}).

Taken together, our preliminary studies exemplify that systemic lipid metabolism is particularly disturbed in the fasted state in mice with metabolic dysfunction, with either enhanced clearance or reduced production of systemic NEFA and TG, the former of which might be explained by a liver‐specific mechanism. Thus, our subsequent studies were focussed on the discovery of a molecular control point regulating (mal)adaptive lipid metabolism during fasting.

Liver GADD45β is an inflexibly regulated gene transcript upon fasting stress in multiple mouse models of metabolic dysfunction {#emmm201505801-sec-0004}
------------------------------------------------------------------------------------------------------------------------------

Previous studies of metabolic tissue transcriptomes in rodents (Bauer *et al*, [2004](#emmm201505801-bib-0008){ref-type="ref"}; Sokolovic *et al*, [2008](#emmm201505801-bib-0072){ref-type="ref"}; Hakvoort *et al*, [2011](#emmm201505801-bib-0033){ref-type="ref"}; Zhang *et al*, [2011](#emmm201505801-bib-0081){ref-type="ref"}; Schupp *et al*, [2013](#emmm201505801-bib-0071){ref-type="ref"}) identified members of the *Gadd45* gene family potently affected by fasting stress. Given that there are three members of the GADD45 family, we then decided to take a targeted approach to the discovery of novel molecular regulatory mechanisms, and examine the expression of all members in multiple models of metabolic dysfunction. To this end, we examined mRNA expression in the liver from the *db*/*db* mice (Fig [2](#emmm201505801-fig-0002){ref-type="fig"}A--C) and observed an upregulation of *Gadd45b* (\~12‐fold; Fig [2](#emmm201505801-fig-0002){ref-type="fig"}B) and *Gadd45g* (\~sevenfold; Fig [2](#emmm201505801-fig-0002){ref-type="fig"}C), which was largely blunted in the liver of db/db mice; with only mild regulation of *Gadd45a* (Fig [2](#emmm201505801-fig-0002){ref-type="fig"}A). Furthermore, we employed less severe models of metabolic dysfunction such as a monogenic model of obesity‐driven pre‐diabetes (Kanasaki & Koya, [2011](#emmm201505801-bib-0037){ref-type="ref"}), the young *ob*/*ob* mouse (data not shown), a polygenic model of obesity‐driven pre‐diabetes, the young New Zealand Obese mouse (NZO; Fig [2](#emmm201505801-fig-0002){ref-type="fig"}D--F) and aged mice (Fig [2](#emmm201505801-fig-0002){ref-type="fig"}G--I). In these models, we could observe a consistent pattern of regulation of *Gadd45b* (Fig [2](#emmm201505801-fig-0002){ref-type="fig"}A, E and H), but not *Gadd45g* (Fig [2](#emmm201505801-fig-0002){ref-type="fig"}C, F and I), with again only mild regulation of *Gadd45a* (Fig [2](#emmm201505801-fig-0002){ref-type="fig"}A, D and G). Importantly, similar to the *Gadd45b* mRNA, which we could show is dynamically regulated upon fasting and refeeding ([Appendix Fig S1A](#emmm201505801-sup-0001){ref-type="supplementary-material"}), we could observe a similar pattern of upregulation of GADD45β protein in the liver of fasted mice, which was absent in the liver of models of metabolic dysfunction (Fig [2](#emmm201505801-fig-0002){ref-type="fig"}J--L). In addition, although we could show mild differential regulation in perigonadal white adipose tissue (pgWAT; [Appendix Fig S1B--D](#emmm201505801-sup-0001){ref-type="supplementary-material"}), brown adipose tissue (BAT; [Appendix Fig S1E--G](#emmm201505801-sup-0001){ref-type="supplementary-material"}) and gastrocnemius complex skeletal muscle (GCM; [Appendix Fig S1H--J](#emmm201505801-sup-0001){ref-type="supplementary-material"}) of *Gadd45a* ([Appendix Fig S1B, E and H](#emmm201505801-sup-0001){ref-type="supplementary-material"}), *Gadd45b* ([Appendix Fig S1C, F and I](#emmm201505801-sup-0001){ref-type="supplementary-material"}) and *Gadd45g* ([Appendix Fig S1D, G and J](#emmm201505801-sup-0001){ref-type="supplementary-material"}) between fed and fasted states comparing lean and obese/T2D mice, none of these regulations were as striking as observed with the liver *Gadd45b* (Fig [2](#emmm201505801-fig-0002){ref-type="fig"}).

![Liver/hepatocyte *Gadd45b* expression is consistently dysregulated upon fasting in several mouse models of metabolic dysfunction\
A--ILiver mRNA expression of growth arrest and DNA damage‐inducible 45 alpha (*Gadd45a*; A, D, G), beta (*Gadd45b*; B, E, H) and gamma (*Gadd45g*; C, F, I) was measured in fed and fasted obese/diabetic monogenic (*db*/*db* (*n* = 4/group); A--C), obese/pre‐diabetic polygenic New Zealand Obese (NZO (*n* = 4/group; D--F) and aged C57Bl/6J (22 months; *n* = 5/group; G--I) as well as corresponding lean, young wild‐type (WT) mice (*n* = 4/group). Matched controls for the NZO and aged mice were New Zealand Black (NZB) and 12‐weeks‐old C57Bl/6J mice, respectively.J--LProtein expression of liver GADD45β, as well as the housekeeping protein valosin‐containing protein (VCP), was measured from liver samples. Number of replicates for each sample set are outlined above.Data information: Data are mean ± SEM. Effect of genotype, \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001. Effect of nutritional state: ^\#^ *P* \< 0.05, ^\#\#^ *P* \< 0.01, ^\#\#\#^ *P* \< 0.001. The statistical test used and respective *P*‐value outputs can be found in [Appendix Table S1](#emmm201505801-sup-0001){ref-type="supplementary-material"}.](EMMM-8-654-g004){#emmm201505801-fig-0002}

GADD45β affects metabolic regulation under conditions of heightened lipid metabolism {#emmm201505801-sec-0005}
------------------------------------------------------------------------------------

Given that we could observe a stark regulation of liver GADD45β under fasting stress, we next tested whether GADD45β expression/activity affects the ability of the organism to handle such nutritional stress by subjecting whole‐body GADD45β knockout mice to starvation and refeeding. In particular, absolute levels as well as changes in body mass (Fig [EV2](#emmm201505801-fig-0002ev){ref-type="fig"}A), food intake (Fig [EV2](#emmm201505801-fig-0002ev){ref-type="fig"}B) and physical activity (Fig [EV2](#emmm201505801-fig-0002ev){ref-type="fig"}C) were unaffected in GADD45β KO mice. Furthermore, systemic oxidative metabolism, as reflected at the rate of O~2~ consumption (Fig [3](#emmm201505801-fig-0003){ref-type="fig"}A), CO~2~ production (Fig [3](#emmm201505801-fig-0003){ref-type="fig"}B) and respiratory exchange ratio (Fig [3](#emmm201505801-fig-0003){ref-type="fig"}C), was also unaffected. In a separate study, we could demonstrate that there was no compensatory upregulation of the other GADD45 family members with loss of GADD45β (Fig [EV2](#emmm201505801-fig-0002ev){ref-type="fig"}D) and could confirm the lack of effect of GADD45β loss on body mass regulation upon starvation (Fig [EV2](#emmm201505801-fig-0002ev){ref-type="fig"}E). When we examined the masses of selected metabolic organs/tissues, there were also no differences (Fig [EV2](#emmm201505801-fig-0002ev){ref-type="fig"}F). On the other hand, while we could not observe any differences in selected liver metabolites (Fig [EV3](#emmm201505801-fig-0003ev){ref-type="fig"}G) or blood serum levels of glucose (Fig [EV2](#emmm201505801-fig-0002ev){ref-type="fig"}H), TG (Fig [3](#emmm201505801-fig-0003){ref-type="fig"}D), ketone bodies (Fig [3](#emmm201505801-fig-0003){ref-type="fig"}E), glycerol (Fig [EV2](#emmm201505801-fig-0002ev){ref-type="fig"}I) and acylcarnitines (Fig [EV2](#emmm201505801-fig-0002ev){ref-type="fig"}J), we could observe a significantly lower increase in serum NEFA (Fig [3](#emmm201505801-fig-0003){ref-type="fig"}F) with a much higher level of accumulation of TG (\~twofold; Fig [3](#emmm201505801-fig-0003){ref-type="fig"}G) in the liver of GADD45β KO mice, pointing to a role for GADD45β in coordinating an aspect of systemic lipid metabolism under starvation stress. Importantly, even though we could observe changes in *Gadd45*γ upon starvation (Fig [2](#emmm201505801-fig-0002){ref-type="fig"}), there was no discernible differential metabolic phenotype in starved GADD45γ KO mice ([Appendix Fig S2](#emmm201505801-sup-0001){ref-type="supplementary-material"}).

![Systemic GADD45β deletion affects metabolic regulation under conditions of heightened lipid metabolism\
A--CMale GADD45β^+/+^ (WT) or GADD45β^−/−^ (KO) were fed *ad libitum* (fed) or fasted for 24 h (fasted), and subsequently refed for 24 h (*n* = 4--6/group). Body weight (A), food intake (B) and physical activity (C) were measured.D--JIn a distinct cohort, male GADD45β^+/+^ (WT) or GADD45β^−/−^ (KO) mice were fasted for 24 h (fasted) (*n* = 5--8/group) with blood samples taken before and during fasting. Liver mRNA expression of *Gadd45* family members (D). Body weight (E) before and after fasting and fasted tissue weights (F). Selected liver metabolites (G) as well as blood glucose (H) and serum glycerol (I) and acylcarnitines (J).Data information; Data are mean ± SEM. Effect of genotype, \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001. Effect of nutritional state: ^\#^ *P* \< 0.05, ^\#\#^ *P* \< 0.01, ^\#\#\#^ *P* \< 0.001. The statistical test used and respective *P*‐value outputs can be found in [Appendix Table S1](#emmm201505801-sup-0001){ref-type="supplementary-material"}.](EMMM-8-654-g005){#emmm201505801-fig-0002ev}

![Systemic GADD45β deletion affects metabolic regulation under conditions of heightened lipid metabolism\
A--GMale GADD45β^+/+^ (WT;*n* = 6) or GADD45β^−/−^ (KO;*n* = 4) mice were fed *ad libitum* (fed) or fasted for 24 h (fasted) and subsequently refed for 24 h. O~2~ consumption rate (A), CO2 production rate (B) and respiratory exchange ratio (C) were measured by indirect calorimetry. In a distinct cohort, male GADD45β^+/+^ (WT;*n* = 5) or GADD45β^−/−^ (KO;*n* = 8) were fed *ad libitum* (fed) or fasted for 24 h (fasted). Serum non‐esterified fatty acids (D) and ketone bodies (E) as well as serum (F) and liver (G) triglycerides (TG) were measured.H--JSerum TG (H), NEFA (I) and blood glucose (BG, J) concentrations during an oral lipid tolerance test in overnight fasted GADD45β^+/+^ (WT;*n* = 5) or GADD45β^−/−^ (KO; *n* = 5) mice.K--NBlood glucose excursion during and intraperitoneal insulin tolerance test (K) as well as fasting blood glucose (L), serum insulin (M) and HOMA‐IR (N) in GADD45β^+/+^ (WT;*n* = 6) or GADD45β^−/−^ (KO,*n* = 9) chronically fed a normal‐ (NFD) or high (HFD)‐fat diet.Data information: Data are mean ± SEM. Effect of genotype, \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001. Effect of nutritional state: ^\#^ *P* \< 0.05, ^\#\#^ *P* \< 0.01, ^\#\#\#^ *P* \< 0.001. The statistical test used and respective *P*‐value outputs can be found in [Appendix Table S1](#emmm201505801-sup-0001){ref-type="supplementary-material"}.](EMMM-8-654-g006){#emmm201505801-fig-0003}

![Liver‐restricted GADD45β manipulation affects systemic metabolic homoeostasis\
A--DAlbumin (A), Cluster of differentiation 31 (B), desmin (C) and EGF‐like module‐containing mucin‐like hormone receptor‐like 1 (D) mRNA expression were measured from fractionated parenchymal hepatocytes (Hepas) as well as non‐parenchymal cells (NP) from C57Bl/6J mice fed *ad libitum* (fed) or fasted for 24 h (fasted) (*n* = 3/group).EMale C57Bl/6J mice with (AAV‐G45b miR) or without (AAV‐NC miR) liver/hepatocyte‐restricted GADD45β silencing were fed or fasted for 24 h (*n* = 6/group). Liver Gadd45b mRNA expression was measured.F--HMale GADD45β^+/+^ (WT) or GADD45β^−/−^ (KO) mice fasted for 24 h (fasted) with (AD‐G45b OE) or without (AD‐NC) liver‐restricted Gadd45b over‐expression (*n* = 7--8/group). Liver mRNA expression of *Gadd45b* (F). Serum non‐esterified fatty acids (G) and triglycerides (H) were measured.I--KMale C57Bl/6J mice with (AAV‐G45b miR) or without (AAV‐NC miR) liver/hepatocyte‐restricted GADD45β silencing were chronically fed a normal‐fat diet (NFD) or high ‐fat diet (HFD) and were sacrificed in the *ad libitum* fed state (*n* = 6--8/group). Body (I), liver (J) and perigonadal white adipose tissue (K) masses.Data information: Data are mean ± SEM. Effect of genotype, \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001. Effect of nutritional state: ^\#^ *P* \< 0.05, ^\#\#^ *P* \< 0.01, ^\#\#\#^ *P* \< 0.001. The statistical test used and respective *P*‐value outputs can be found in [Appendix Table S1](#emmm201505801-sup-0001){ref-type="supplementary-material"}.](EMMM-8-654-g007){#emmm201505801-fig-0003ev}

Given that we could detect changes in lipid metabolism during starvation, we next directly tested lipid homoeostasis by conducting an oral lipid tolerance test. Strikingly, systemic lipid clearance was accelerated in fasted GADD45β KO mice, with substantially lower serum TG (Fig [3](#emmm201505801-fig-0003){ref-type="fig"}H) and NEFA (Fig [3](#emmm201505801-fig-0003){ref-type="fig"}I). Perhaps surprisingly, blood glucose levels rose to a greater extent in the GADD45β KO mice following oral lipid provision (Fig [3](#emmm201505801-fig-0003){ref-type="fig"}J), indicating that GADD45β might be a molecular regulator of lipid--glucose metabolic crosstalk. To test this further, we conducted a chronic high‐fat diet (HFD) study, which should then reveal whether GADD45β is operative in affecting metabolic control during more mild but chronic fasting‐feeding rhythms, and while there were no substantial effects of GADD45β loss on glucose homoeostasis on the normal‐fat diet (NFD), there was impaired glucose homoeostasis upon high‐fat diet treatment as demonstrated by intraperitoneal insulin tolerance testing (ipITT; Fig [3](#emmm201505801-fig-0003){ref-type="fig"}K) as well as fasting glucose (BG; Fig [3](#emmm201505801-fig-0003){ref-type="fig"}J), insulin (Fig [3](#emmm201505801-fig-0003){ref-type="fig"}M) and a calculated insulin resistance index (HOMA‐IR; Fig [3](#emmm201505801-fig-0003){ref-type="fig"}N), which were independent of compensatory GADD45 expression, body and liver mass in the *ad libitum* fed state ([Appendix Fig S3](#emmm201505801-sup-0001){ref-type="supplementary-material"}).

Liver GADD45β modulates metabolic regulation under conditions of heightened lipid metabolism {#emmm201505801-sec-0006}
--------------------------------------------------------------------------------------------

We next wanted to test whether liver‐specific GADD45β affects systemic metabolism. Indeed, we could demonstrate that similar to the lipid tolerance test results (Fig [3](#emmm201505801-fig-0003){ref-type="fig"}C and D), *ex vivo* liver lipid handling is affected by GADD45β loss (Fig [4](#emmm201505801-fig-0004){ref-type="fig"}A--D), selectively in the fasted state when *Gadd45b* is upregulated (Fig [2](#emmm201505801-fig-0002){ref-type="fig"}). In particular, long‐chain fatty acid uptake was enhanced (LCFA; Fig [4](#emmm201505801-fig-0004){ref-type="fig"}A), without effects on LCFA oxidation (Fig [4](#emmm201505801-fig-0004){ref-type="fig"}B), and thus largely driven by an enhanced non‐oxidative metabolism (NOFAD; Fig [4](#emmm201505801-fig-0004){ref-type="fig"}C). Similar to the exaggerated glycemic response to oral lipid (Fig [3](#emmm201505801-fig-0003){ref-type="fig"}E), the glucose production rate from liver *ex vivo* was exacerbated by GADD45β loss (Fig [4](#emmm201505801-fig-0004){ref-type="fig"}D), highlighting a potential role of GADD45β in coordinating proper liver fatty acid--glucose metabolism crosstalk.

![Liver GADD45β modulates metabolic regulation under conditions of heightened lipid metabolism\
A--DMale,GADD45β^+/+^ (WT) or GADD45β^−/−^ (KO) mice were fed *ad libitum* (fed) or fasted for 24 h (fasted), and *ex vivo* liver slice long‐chain fatty acid (LCFA) metabolism was measured including LCFA uptake (A), oxidation (B) and non‐oxidative LCFA disposal (NOFAD) was calculated (C). In addition, glucose production was measured (D) in the presence (BSA‐NEFA) or absence (BSA) of extracellular fatty acids (A‐D: *n* = 4/group with four liver slices per mouse liver).E*Gadd45b* mRNA expression was measured from fractionated parenchymal hepatocytes (Hepas) as well as non‐parenchymal cells (NP) from C57Bl/6J mice fed *ad libitum* (fed) or fasted for 24 h (fasted); *n* = 3/group.F, GMale C57Bl/6J mice with (AAV‐G45b miR) or without (AAV‐NC miR) liver/hepatocyte‐restricted GADD45β silencing were fed or fasted for 24 h (*n* = 6/group), and serum levels of non‐esterified fatty acids (NEFA; F) as well as liver triglyceride (TG) concentration (G) were measured.HMale GADD45β^+/+^ (WT;*n* = 16) or GADD45β^−/−^ (KO;*n* = 15) mice fasted for 24 h (fasted) with (AD‐G45b OE) or without (AD‐NC) liver‐restricted GADD45β over‐expression (*n* = 7--8/group). Liver TG concentration was measured.I--KMale C57Bl/6J mice with (AAV‐G45b miR; *n* = 15) or without (AAV‐NC miR, *n* = 13) liver/hepatocyte‐restricted GADD45β silencing were chronically fed a normal‐fat diet (NFD) or high ‐fat diet (HFD) (*n* = 6--8/group). Fasting blood glucose (I) and serum insulin (J) were measured from which HOMA‐IR was calculated (K).Data information: Data are mean ± SEM. Effect of genotype/viral manipulation, \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001. Effect of nutritional state: ^\#^ *P* \< 0.05, ^\#\#^ *P* \< 0.01, ^\#\#\#^ *P* \< 0.001. The statistical test used and respective *P*‐value outputs can be found in [Appendix Table S1](#emmm201505801-sup-0001){ref-type="supplementary-material"}.](EMMM-8-654-g008){#emmm201505801-fig-0004}

To examine whether the upregulation of *Gadd45b* mRNA during fasting was occurring within the parenchymal cell of the liver, namely the hepatocyte, we performed a liver cell‐type fractionation experiment from livers of fasted and fed mice. While the fractionation of hepatocytes leaked into the non‐parenchymal fraction to a mild extent (*Alb*; Fig [EV3](#emmm201505801-fig-0003ev){ref-type="fig"}A), the hepatocyte fraction was devoid of non‐parenchymal markers of endothelial (*Cd31*; Fig [EV3](#emmm201505801-fig-0003ev){ref-type="fig"}B), stellate (*Des*; Fig [EV3](#emmm201505801-fig-0003ev){ref-type="fig"}C) and Kupffer (*Emr1*; Fig [EV3](#emmm201505801-fig-0003ev){ref-type="fig"}D) cells, and there was only an upregulation of *Gadd45b* in the hepatocyte fraction (Fig [4](#emmm201505801-fig-0004){ref-type="fig"}E), indicating that the increase of *Gadd45b* expression within the liver upon fasting occurs within the hepatocyte.

Given the above findings, we then wanted to assess whether GADD45β affects metabolic control in a liver‐specific manner *in vivo*. As such, we conducted a study whereby we silenced *Gadd45b* in a liver/hepatocyte selective manner (Graham *et al*, [2008](#emmm201505801-bib-0031){ref-type="ref"}; Rose *et al*, [2011](#emmm201505801-bib-0067){ref-type="ref"}) via AAV‐mediated delivery of a *Gadd45b*‐specific miRNA. Using this strategy, we were able to substantially blunt the expression of *Gadd45b*, particularly during fasting (Fig [EV3](#emmm201505801-fig-0003ev){ref-type="fig"}E). Similar to the results from the germline whole‐body KO (Fig [3](#emmm201505801-fig-0003){ref-type="fig"}), there was a blunting of the higher serum NEFA (Fig [4](#emmm201505801-fig-0004){ref-type="fig"}F) and exacerbation of the higher liver TG (Fig [4](#emmm201505801-fig-0004){ref-type="fig"}G) in the fasted liver‐specific *Gadd45b* silenced mice. To confirm that hepatic GADD45β affects lipid metabolism, we conducted a study whereby we overexpressed GADD45β in the liver in GADD45β KO mice (Fig [EV3](#emmm201505801-fig-0003ev){ref-type="fig"}F). Indeed, GADD45β re‐introduction into the liver of whole‐body GADD45β KO, despite not affecting serum NEFA (Fig [EV3](#emmm201505801-fig-0003ev){ref-type="fig"}G), affected serum TG (Fig [EV3](#emmm201505801-fig-0003ev){ref-type="fig"}H) and alleviated the heightened accumulation of TG in the liver of GADD45β KO mice upon fasting (Fig [4](#emmm201505801-fig-0004){ref-type="fig"}H). To test this further, we conducted a chronic high‐fat diet (HFD) study, which should then reveal whether GADD45β is operative in affecting metabolic control during more mild but chronic fasting‐feeding rhythms. While there were no substantial effects of GADD45β loss on biometric parameters (Fig [EV3](#emmm201505801-fig-0003ev){ref-type="fig"}I--K), similar to the whole‐body KO study (Fig [3](#emmm201505801-fig-0003){ref-type="fig"}), hepatocyte‐specific GADD45β silencing worsened the progression of insulin resistance upon high‐fat diet‐induced obesity (Fig [4](#emmm201505801-fig-0004){ref-type="fig"}I--K).

Impaired liver GADD45β expression correlates with metabolic dysfunction in obesity‐driven type 2 diabetes in mouse and man {#emmm201505801-sec-0007}
--------------------------------------------------------------------------------------------------------------------------

Prompted by our results that GADD45β loss can affect glucose homoeostasis in obesity (Figs [3](#emmm201505801-fig-0003){ref-type="fig"} and [4](#emmm201505801-fig-0004){ref-type="fig"}), we tested whether restoration of liver GADD45β can improve metabolic homoeostasis in type 2 diabetes. To this end, we employed our prior strategy and overexpressed GADD45β in the liver of obese/diabetic *db*/*db* mice (Fig [EV4](#emmm201505801-fig-0004ev){ref-type="fig"}A). While biometrics (Fig [EV4](#emmm201505801-fig-0004ev){ref-type="fig"}B--D) were not drastically affected, fasting blood glucose (Fig [5](#emmm201505801-fig-0005){ref-type="fig"}A) and insulin (Fig [5](#emmm201505801-fig-0005){ref-type="fig"}B) were lower in diabetic mice, which led to an overall reduction in systemic insulin resistance (HOMA‐IR; Fig [5](#emmm201505801-fig-0005){ref-type="fig"}C). Since GADD45β expression in liver affects lipid and glucose homoeostasis in mice, we wondered if the same were true in humans. Indeed, during fasting, *GADD45B* expression was significantly lower in livers of type‐2 diabetic patients (T2D) when compared with aged‐matched individuals with normal glucose tolerance (NGT; Fig [5](#emmm201505801-fig-0005){ref-type="fig"}D). Furthermore, although there was a non‐significant negative correlation with HOMA‐IR (Fig [EV4](#emmm201505801-fig-0004ev){ref-type="fig"}E), liver *GADD45B* expression negatively correlated with fasting TG (Fig [5](#emmm201505801-fig-0005){ref-type="fig"}E) and glucose (FPG; Fig [5](#emmm201505801-fig-0005){ref-type="fig"}F) levels. Hence, similar to mice, effective *GADD45B* expression during fasting may also confer proper metabolic control in humans.

![Liver GADD45β expression modulates metabolic control in type 2 diabetes\
A--DMale 12‐weeks‐old wild‐type (WT; C57Bl/6J) or obese/diabetic (*db*/*db*;BKS.Cg‐m^+/+^ Lepr DB/J) mice with (AD‐G45b OE) or without (AD‐NC) liver‐restricted GADD45β over‐expression were fasted for 24 h (*n* = 4--6/group). Liver mRNA expression of *Gadd45b* (A). Body mass (B), the change in body mass during the experiment (C) and liver mass (D). Data are mean ± SEM. Effect of genotype, \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001. Effect of viral manipulation state: ^\#^ *P* \< 0.05, ^\#\#^ *P* \< 0.01, ^\#\#\#^ *P* \< 0.001.EFasting HOMA‐IR in correlation with liver *GADD45B* mRNA expression in men as in Fig [5](#emmm201505801-fig-0005){ref-type="fig"} (*n* = 37). Inserts show *r* ^2^ values and *P*‐values from Spearman\'s correlation test.Data information: The statistical test used and respective *P*‐value outputs can be found in [Appendix Table S1](#emmm201505801-sup-0001){ref-type="supplementary-material"}.](EMMM-8-654-g009){#emmm201505801-fig-0004ev}

![Liver GADD45β expression modulates glucose homoeostatic control in type 2 diabetes\
A--CMale 12‐weeks‐old wild‐type (WT; C57Bl/6J) or obese/diabetic (*db*/*db*;BKS.Cg‐m^+/+^ Lepr DB/J) mice with (AD‐G45b OE) or without (AD‐NC) prior liver‐restricted GADD45β over‐expression were fasted, and blood glucose (A) and serum insulin (B) were measured from which HOMA‐IR was calculated (C) (*n* = 4--6/group). Data are mean ± SEM. Effect of genotype/viral manipulation, \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001. Effect of nutritional state: ^\#^ *P* \< 0.05, ^\#\#^ *P* \< 0.01, ^\#\#\#^ *P* \< 0.001.D--FLiver *GADD45B* mRNA expression from men with (T2D) or without (NGT) type 2 diabetes (*n* = 14--23/group). \*\*\**P* \< 0.001. Scatter plots fasting plasma triglycerides (E) and glucose (F) in correlation with liver *GADD45B* mRNA expression (*n* = 37). Inserts show *r* ^2^ values and *P*‐values from Spearman\'s correlation test.Data information: The statistical test used and respective *P*‐value outputs can be found in [Appendix Table S1](#emmm201505801-sup-0001){ref-type="supplementary-material"}.](EMMM-8-654-g010){#emmm201505801-fig-0005}

Liver GADD45β controls liver fatty acid handling by cytosolic FABP1 retention {#emmm201505801-sec-0008}
-----------------------------------------------------------------------------

Given the effects of GADD45β on metabolism, we then searched for a mechanism by which it might exert such control. Given that prior studies have demonstrated a role for GADD45β to control various aspects of cellular functions though transcriptional or signalling mechanisms we first focussed on this. In particular, overexpression of GADD45β in the livers of diabetic mice did not enhance key insulin signalling nodes (Fig [EV5](#emmm201505801-fig-0005ev){ref-type="fig"}A and B). Furthermore, although previously implicated in other studies (Keil *et al*, [2013](#emmm201505801-bib-0039){ref-type="ref"}; Tian & Locker, [2013](#emmm201505801-bib-0076){ref-type="ref"}), GADD45β expression did not affect autophagy, mTORC1, MAPK or ER stress signalling pathways (Fig [EV5](#emmm201505801-fig-0005ev){ref-type="fig"}C and D). Nor did GADD45β (Fig [6](#emmm201505801-fig-0006){ref-type="fig"}A) affect expression of key genes involved in liver fatty acid transport/metabolism at the mRNA (Fig [6](#emmm201505801-fig-0006){ref-type="fig"}B) or protein (Fig [EV5](#emmm201505801-fig-0005ev){ref-type="fig"}C and D) level. Consistent with a role for localisation of key FA transport/handling proteins in metabolic control (Glatz *et al*, [2002](#emmm201505801-bib-0028){ref-type="ref"}; Kazantzis & Stahl, [2012](#emmm201505801-bib-0038){ref-type="ref"}), we could, however, observe a role for GADD45β in regulating FABP1, but not FATP2 nor CD36, localisation (Fig [6](#emmm201505801-fig-0006){ref-type="fig"}C). In particular, FABP1 localisation was redistributed from the cytoplasm to the low‐density microsomal (i.e. plasma membrane and microsomes) membranes with a lack of GADD45β (Figs [6](#emmm201505801-fig-0006){ref-type="fig"}C and D, and [EV5](#emmm201505801-fig-0005ev){ref-type="fig"}E), which could be reversed by re‐expression of GADD45β in a liver‐specific manner (Fig [6](#emmm201505801-fig-0006){ref-type="fig"}E). Furthermore, similar to the liver of GADD45β knockout mice, obese/diabetic db/db mice had a redistribution of FABP1 towards microsomes and away from the cytosol, which could be reversed by GADD45B overexpression (Fig [6](#emmm201505801-fig-0006){ref-type="fig"}F).

![Liver GADD45β controls liver fatty acid handling by cytosolic FABP1 retention\
A, BMale 12‐weeks‐old wild‐type (WT; C57Bl/6J) or obese/diabetic (*db*/*db*;BKS.Cg‐m^+/+^ Lepr DB/J) mice with (Ad‐G45b OE) or without (Ad‐NC) prior liver‐restricted GADD45β over‐expression were fasted and insulin was injected with livers harvested shortly thereafter and subsequently liver proteins were subjected to immunoblotting for insulin signalling proteins including phosphoprotein kinase B (PKB/Akt; A) and glycogen synthase kinase beta (GSK3b; B). Inserts show representative blots (*n* = 6/group).C, DRepresentative immunoblots (C) and relative abundance quantifications (D; *n* = 6) of proteins and phosphoproteins including light chain 3 isoform B (LC3B), S6 kinase 1 (S6K1), p42/44 mitogen activated protein kinase (ERK1/2), eukaryotic initiation factor 2 alpha (eIF2a), glucose regulated protein 78 (GRP78/HSPA5), fatty acid transport protein 2 (FATP2/SLC27A2), cluster determinant 36 (CD36/FAT) and fatty acid binding protein 1 (FABP1) from fasted GADD45β^+/+^ (WT) or GADD45β^−/−^ (KO) mice.ERepresentative immunoblots of HNF4a (nuclear marker), BCKDE1A (mitochondrial marker), NTCP (microsomal marker) and ARG1 (cytosolic marker) from liver whole tissue lysate (W) as well as fractionated organelles/intraceuular structures including nuclei (N), mitochondria (MT), microsomes (MS) and cytoplasm (C), from GADD45β^+/+^ (WT) and GADD45β^−/−^ (KO) mice.Data information: Data are mean ± SEM. The statistical test used and respective *P*‐value outputs can be found in [Appendix Table S1](#emmm201505801-sup-0001){ref-type="supplementary-material"}.](EMMM-8-654-g011){#emmm201505801-fig-0005ev}

![Liver GADD45β controls liver fatty acid handling by cytosolic FABP1 retention\
A, BMale GADD45β^+/+^ (WT;*n* = 16) or GADD45β^−/−^ (KO;*n* = 15) mice fasted for 24 h (fasted) with (AV‐G45b OE) or without (AV‐NC) liver‐restricted GADD45β over‐expression (*n* = 7--8/group). Liver mRNA expression of Gadd45b (A) as well as fatty acid metabolic genes (B) encompassing transport (Slc28a2, Slc27a5, Cd36), intracellular binding (Fabp1, Dbi) and metabolism (Acly, Dgat1, Atgl, Hsl).CRepresentative immunoblots of FATP2, CD36, FABP1 and GADD45β from liver whole tissue lysate (W) as well as fractionated organelles/intracellular structures including nuclei (N), mitochondria (MT), microsomes (MS) and cytoplasm (C), from GADD45β^+/+^ (WT) and GADD45β^−/−^ (KO) mice.DQuantified band densities of FABP1 enrichment from fractions in C (*n* = 4/group).ELiver fraction enrichment of FABP1 from male GADD45β^+/+^ (WT) or GADD45β^−/−^ (KO) mice fasted for 24 h with (AD‐G45b OE) or without (AD‐NC) liver‐restricted GADD45β over‐expression (*n* = 4/group). Insert shows a representative FABP1 immunoblot.FLiver fraction enrichment of FABP1 from obese/diabetic male *db*/*db* mice fasted for 24 h with (AD‐G45b OE) or without (AD‐NC) liver‐restricted GADD45β over‐expression (*n* = 4/group). Insert shows a representative FABP1 immunoblot.GFABP1 and GADD45B immunoblots from Flag immunoprecipitations (IP‐FLAG) or mock IP (IP‐HA) from liver input samples from mice with (AD‐G45b OE) or without (AD‐NC) liver‐restricted GADD45β over‐expression. Shown is a representative immunoblot from 3 separate experiments using 3 different input samples per condition.H--JLiver tissue long‐chain acyl‐CoA (LC‐acyl‐CoA) concentrations were determined in GADD45β^+/+^ (WT) or GADD45β^−/−^ (KO) mice (H; *n* = 6/group) with (AD‐G45b OE) or without (AD‐NC) liver‐restricted GADD45β over‐expression (I; *n* = 5/group). Liver LC‐acyl‐CoA concentrations were determined in wild‐type (WT; C57Bl/6J) or obese/diabetic (*db*/*db*;BKS.Cg‐m^+/+^ Lepr DB/J) mice with (AD‐G45b OE) or without (AD‐NC) liver‐restricted GADD45β over‐expression (J; *n* = 4/group).Data information: Data are mean ± SEM. Effect of genotype, \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001. Effect of viral manipulation: ^\#^ *P* \< 0.05, ^\#\#^ *P* \< 0.01, ^\#\#\#^ *P* \< 0.001. The statistical test used and respective *P*‐value outputs can be found in [Appendix Table S1](#emmm201505801-sup-0001){ref-type="supplementary-material"}.](EMMM-8-654-g012){#emmm201505801-fig-0006}

Given that immunoprecipitation experiments demonstrated that GADD45β can physically bind in a complex with FABP1 (Fig [6](#emmm201505801-fig-0006){ref-type="fig"}G) and that GADD45β is exclusively expressed in the cytoplasm (Fig [6](#emmm201505801-fig-0006){ref-type="fig"}C), GADD45β might operate as a cytosolic adapter molecule for FABP1. Lastly, expression of GADD45β and associated altered localisation of FABP1 consistently negatively correlated with liver levels of activated long‐chain fatty acids in multiple experiments (Fig [6](#emmm201505801-fig-0006){ref-type="fig"}H--J), consistent with a direct role for GADD45β to modulate hepatocellular FA metabolism.

Discussion {#emmm201505801-sec-0009}
==========

Here, we demonstrate that liver GADD45β expression is dynamically regulated upon fasting stress, perhaps by increased oxidative stress (Zhang *et al*, [2013](#emmm201505801-bib-0082){ref-type="ref"}; Kim *et al*, [2014](#emmm201505801-bib-0040){ref-type="ref"}), where it aids in the coordination of liver lipid metabolism, by limiting hepatocellular fatty acid (FA) uptake via cytosolic FABP1 retention. Furthermore, in mouse and human metabolic dysfunction such as type 2 diabetes, obesity/pre‐diabetes and the aged, liver GADD45β expression is dysregulated thereby contributing to aberrant lipid/glucose homoeostasis.

The GADD45 gene family composes of three structurally and functionally related genes named as GADD45α, GADD45β and GADD45γ, encoding small, highly acidic, nuclear proteins (Liebermann & Hoffman, [2002](#emmm201505801-bib-0049){ref-type="ref"}). Depending on the cellular stress and the physical interactions with other proteins, GADD45 proteins serve as stress sensors, which participate in cell cycle arrest, apoptosis and cell survival (Liebermann & Hoffman, [2008](#emmm201505801-bib-0050){ref-type="ref"}). Despite their structural and physical similarities, their response to stress conditions is cell type and stimulus specific (Yang *et al*, [2009](#emmm201505801-bib-0080){ref-type="ref"}). Indeed, similar to prior studies (Bauer *et al*, [2004](#emmm201505801-bib-0008){ref-type="ref"}; Zhang *et al*, [2011](#emmm201505801-bib-0081){ref-type="ref"}), here, we could show that fasting preferentially promotes GADD45β expression in the liver, whereas others have demonstrated that physical exertion (Hoene & Weigert, [2010](#emmm201505801-bib-0035){ref-type="ref"}), cold stress (Gantner *et al*, [2014](#emmm201505801-bib-0027){ref-type="ref"}) and atrophy (Ebert *et al*, [2012](#emmm201505801-bib-0023){ref-type="ref"}) activated GADD45 isoform expression in other diverse metabolic tissues, with functional metabolic effects. Furthermore, there are several lines of evidence that GADD45β is involved in hyperplasia of hepatocytes in liver regeneration (Columbano *et al*, [2005](#emmm201505801-bib-0018){ref-type="ref"}; Papa *et al*, [2008](#emmm201505801-bib-0062){ref-type="ref"}; Tian *et al*, [2011](#emmm201505801-bib-0075){ref-type="ref"}), and although hepatic TG accumulation occurs during liver regeneration, the effects GADD45β on lipid metabolism identified here are unlikely to be of relevance in this setting (Newberry *et al*, [2008](#emmm201505801-bib-0060){ref-type="ref"}). Even though GADD45β has been linked to epigenetic control (Ma *et al* [2009](#emmm201505801-bib-0800){ref-type="ref"}), it is unlikely that the altered metabolism observed within GADD45β knockout mice results from developmental "programming" as we could show congruent phenotypes when GADD45β was manipulated in adult mice.

Through liver‐specific GADD45β manipulation *in vivo,* we demonstrated that the altered liver fatty acid metabolism in obesity/diabetes and ageing might result from altered liver GADD45β expression, particularly during the fasted state. In particular, fasted obese/T2D mice had enhanced liver LCFA uptake, with a similar phenotype observed in fasted GADD45β KO mice, suggesting that the blunted regulation of liver GADD45β and metabolic derangements in mouse models of metabolic dysfunction may be causally linked. We speculate that the persistent fast‐feeding cycles intermittently activate liver GADD45β expression, leading to proper coordination of liver lipid metabolism during fasting, ultimately impacting the maintenance of metabolic health, particularly when dietary lipid/nutrient intake is high. Indeed, liver lipid metabolism is intimately linked to systemic glucose control (Perry *et al*, [2015](#emmm201505801-bib-0064){ref-type="ref"}).

While it is conceivable that GADD45β could achieve its effects via both cell‐autonomous and non‐autonomous mechanisms, we could demonstrate that GADD45β modulates LCFA metabolism *ex vivo*, indicating that the former is likely to be the case, and that factors within hepatocytes *per se* are likely to be affected by GADD45β. In particular, unlike other studies that have shown a role for the activation of transcriptional co‐activator PGC1α to retard metabolic dysfunction by promoting fatty acid oxidation (Morris *et al*, [2012](#emmm201505801-bib-0057){ref-type="ref"}), we could demonstrate that fasting liver LCFA oxidation was not affected, but rather non‐oxidative FA metabolism independent of storage was involved in GADD45β‐mediated effects on hepatic lipid metabolism. This is reminiscent of studies of skeletal muscle, where an unknown FA metabolic fate correlates with obesity‐related metabolic dysfunction (Koves *et al*, [2008](#emmm201505801-bib-0045){ref-type="ref"}), and probably relates to a relative mitochondrial substrate "overload" (Muoio & Neufer, [2012](#emmm201505801-bib-0058){ref-type="ref"}), which seems to be also present in the liver (Satapati *et al*, [2012](#emmm201505801-bib-0069){ref-type="ref"}). Furthermore, chronically enhanced liver FA supply/uptake can negatively affect systemic metabolic function (Mittelman *et al*, [1997](#emmm201505801-bib-0056){ref-type="ref"}; Koonen *et al*, [2007](#emmm201505801-bib-0044){ref-type="ref"}; Doege *et al*, [2008](#emmm201505801-bib-0022){ref-type="ref"}; Falcon *et al*, [2010](#emmm201505801-bib-0025){ref-type="ref"}; Perry *et al*, [2015](#emmm201505801-bib-0064){ref-type="ref"}) the mechanisms by which are not fully resolved. On this, we could demonstrate that induced GADD45β restrained liver fatty acid uptake during fasting ultimately preventing an accumulation of long‐chain (LC) acyl‐CoAs in the liver. Given that liver LC‐acyl‐CoAs levels positively correlate with insulin resistance (present work and (Chen *et al*, [1992](#emmm201505801-bib-0017){ref-type="ref"}; Kamath *et al*, [2011](#emmm201505801-bib-0036){ref-type="ref"}), they may be directly or indirectly related to aberrant glucose metabolism under conditions of enhanced fatty acid supply such as obesity (Li *et al*, [2010](#emmm201505801-bib-0048){ref-type="ref"}), the mechanisms by which are likely to be diverse (Faergeman & Knudsen, [1997](#emmm201505801-bib-0024){ref-type="ref"}; Cooney *et al*, [2002](#emmm201505801-bib-0020){ref-type="ref"}; Li *et al*, [2010](#emmm201505801-bib-0048){ref-type="ref"}). Indeed, here we observed that restoration of low liver GADD45β expression in obese/diabetic mice reduced the higher liver LC‐acyl‐CoA amount in liver, which correlated with improved glucose homoeostasis.

Here, we demonstrate that GADD45β binds to and restrains FABP1 to the hepatocyte cytoplasmic compartment, ultimately preventing an accumulation of activated long‐chain fatty acids. Importantly, although normally heavily abundant in the cytoplasm, redistribution of FABP1 has been described previously in other contexts (Wolfrum *et al*, [2001](#emmm201505801-bib-0079){ref-type="ref"}; Antonenkov *et al*, [2006](#emmm201505801-bib-0002){ref-type="ref"}). Consistent with a key role for FABP1 localisation in explaining the altered FA metabolism modulated by GADD45β expression, FABP1 is a highly abundant protein in the liver which has a role in cellular uptake of FAs and affects the development of insulin resistance in obesity (Atshaves *et al*, [2010](#emmm201505801-bib-0004){ref-type="ref"}). In particular, *in vitro* gain‐ and loss‐of‐function studies (Wolfrum *et al*, [2001](#emmm201505801-bib-0079){ref-type="ref"}; Linden *et al*, [2002](#emmm201505801-bib-0051){ref-type="ref"}; Newberry *et al*, [2003](#emmm201505801-bib-0059){ref-type="ref"}) have implicated FABP1 in hepatocellular FA uptake, and studies of germline FABP1 knockout mice demonstrate reduced hepatic FA uptake particularly during conditions of heightened FA supply such as fasting (Martin *et al*, [2003](#emmm201505801-bib-0054){ref-type="ref"}; Newberry *et al*, [2003](#emmm201505801-bib-0059){ref-type="ref"}), which is consistent with our studies here. Thus, we hypothesise that aberrant localisation of FABP1 towards microsomal membranes, including the surface membranes and microsomes, is a molecular event linking excess hepatic fatty acid uptake and low GADD45β expression during fasting.

Of note, the aberrant lipid metabolic phenotype, including serum NEFA, triglycerides, ketone bodies, acylcarnitines and liver triglycerides, of obese/aged mice was particularly observed in the fasted state, which corresponds to studies in humans demonstrating that differential metabolic phenotypes are best revealed by challenges (Krug *et al*, [2012](#emmm201505801-bib-0046){ref-type="ref"}). In flies, D‐GADD45 overexpression results in increased longevity, and a hallmark of long‐lived animals is resistance to stressors (Calabrese *et al*, [2011](#emmm201505801-bib-0016){ref-type="ref"}). Indeed, we (data not shown) and others (Kim *et al*, [2015](#emmm201505801-bib-0041){ref-type="ref"}) have demonstrated that GADD45β protects against liver damage upon toxicity stress and fasting activates pleiotropic adaptive processes that are beneficial to organismal health (Longo & Mattson, [2014](#emmm201505801-bib-0053){ref-type="ref"}). Given that liver toxicity response is exacerbated in obese/diabetic mice (Aubert *et al*, [2012](#emmm201505801-bib-0005){ref-type="ref"}), of which have dysregulated GADD45β expression, the coordination of metabolism by GADD45β may represent of molecular metabolic link in adaptive stress biology. Taken together, we hypothesise that GADD45β might represent a "vitagene" conferring hormetic metabolic adaptive processes (Calabrese *et al*, [2011](#emmm201505801-bib-0016){ref-type="ref"}), and that the concept of "metabolic inflexibility" (Storlien *et al*, [2004](#emmm201505801-bib-0073){ref-type="ref"}) may simply reflect a lack of response of such hormetic mechanisms (Kolb & Eizirik, [2012](#emmm201505801-bib-0043){ref-type="ref"}), of which liver GADD45β induction may be one component.

In summary, here, we identify a role of a liver transcript, GADD45β, in modulating systemic and liver‐specific adaptive metabolism under nutrient‐starvation stress, which ultimately aids in the coordination of metabolic homoeostasis upon chronic nutrient overload.

Materials and Methods {#emmm201505801-sec-0010}
=====================

Mouse experiments {#emmm201505801-sec-0011}
-----------------

Mouse strains used included male wild‐type C57Bl/6J (000664; Charles River Laboratories, DEU), *db*/*db* (12 weeks; 000642, BKS.Cg‐m^+/+^ Lepr DB/J, Charles River Laboratories, DEU), *ob*/*ob* (7 weeks; 000632, B6.Cg‐*Lep* ^*ob*^/J, Jackson Laboratories, USA), New Zealand Black (7 weeks; NZB/BlNJ, 000993, Jackson Laboratories, USA) and New Zealand Obese (7 weeks; NZO/HlLtJ, 002105, Jackson Laboratories, USA). Furthermore, germline male GADD45β (B6.CgGADD45β^tm1Daa^; Gupta *et al*, [2005](#emmm201505801-bib-0032){ref-type="ref"}) and female (XX) GADD45γ (B6.CgGADD45γ^tm1Mhol^; Cai *et al*, [2006](#emmm201505801-bib-0015){ref-type="ref"}) knockout mice from ^−/+^ × ^−/+^ crossings were used. Importantly, SNP marker testing demonstrated that the GADD45β mouse line was of 99.1% pure C57Bl/6 background strain (Charles River Genetic Testing Services; data not shown). The animals were housed according to international standard conditions with a 12‐h dark--light cycle and regular unrestricted diet with free access to water if not stated otherwise. For studies with overexpression of GADD45β in the murine liver, 1 × 10^9^ infectious units per recombinant adenovirus (AD) were administered via tail vein injection into either male *db*/*db* and C57Bl/6J control mice or GADD45β WT and KO littermates 1 week after acclimation on control diet, all at the age of 12 weeks. Another week later, mice were fasted for 24 h before sacrifice. In other studies, hepatocyte‐specific GADD45β knockdown was accompanied with fasting or HFD treatments. After 1 week of acclimation on control diet, at the age of 9 weeks, 2 × 10^11^ virus particles per adeno‐associated virus (AAV) were administered via tail vein injection into male C57Bl/6J mice. The fasting study was carried out, half the mice from each virus group either fed *ad libitum* or were subjected for fasting for 24 h. For the HFD study, 1 week after virus administration, half of the animals switched to HFD and studied for further 16 weeks. Inclusion criteria were mice of a certain age (i.e. 9--12 weeks at the beginning of the experiment. Criteria for exclusion of mice from study groups were obvious infections/wounds which would impact on feeding behaviour as well as metabolic profile. These criteria were pre‐established. Animal experiments were conducted according to local, national and EU ethical guidelines and approved by local regulatory authorities (Regierungspräsidium Karlsruhe, DEU) and conformed to ARRIVE guidelines.

Metabolic phenotyping {#emmm201505801-sec-0012}
---------------------

For starvation experiments, mice were placed in fresh cages and food was withdrawn while maintain access to drinking water for 24 h from ZT1. For all GADD45 experiments, a control diet (Research diets D12450B, New Brunswick, USA) was used, and experiments were conducted after at least 1‐week adaptation to the diet. To study diet‐induced obesity, a high‐fat diet was used (Research diets D12492, New Brunswick, USA). For comprehensive metabolic/behavioural phenotyping, the TSE Phenomaster system was used that permits automated and simultaneous monitoring of indirect calorimetry, body mass, food and water intake and 3D activity of individually housed mice (Tschop *et al*, [2012](#emmm201505801-bib-0077){ref-type="ref"}). Mice were acclimated to the system 4 days prior to the initiation of the experiments. For standard experiments, blood was taken after cervical dislocation and organs including liver, adipose tissue depots and gastrocnemius muscles were collected, weighed, snap‐frozen in liquid nitrogen and stored at −80°C until further analysis.

To study the dynamics of systemic metabolism, we performed tolerance tests according to established guidelines (Ayala *et al*, [2010](#emmm201505801-bib-0006){ref-type="ref"}). In particular, we performed an intraperitoneal insulin (1 IU/kg; Huminsulin Normal, DEU) tolerance test in the 5--6 h fasted state between ZT5‐9. An oral lipid (100 μl/mouse olive oil delivered by oral gavage; O1514, Sigma‐Aldrich, DEU) tolerance test was conducted in the overnight (i.e. 14--16 h) fasted state between ZT1‐4. Furthermore, blood samples were collected from the tail vein in the 5--6 h fasted state (ZT6‐7) for assessment of blood glucose and serum insulin levels for the calculation of HOMA‐IR ((glucose (mM) × insulin (pM))/3857), which is a good surrogate measure of whole‐body insulin action in mice (Lee *et al*, [2008](#emmm201505801-bib-0047){ref-type="ref"}). To assess tissue‐specific insulin signalling, mice were fasted for 6 h, then insulin (Huminsulin, Lilly) was injected (10 mU/g body weight) and 15 min later, liver tissue was rapidly harvested and frozen in LN~2~ following euthanisation by cervical dislocation (Agouni *et al*, [2010](#emmm201505801-bib-0001){ref-type="ref"}).

Human subjects {#emmm201505801-sec-0013}
--------------

Liver tissue samples were obtained from 37 Caucasian lean and obese men, 14 with and 23 without type 2 diabetes, who underwent open abdominal surgery for Roux‐en‐Y bypass, sleeve gastrectomy or elective cholecystectomy. Liver biopsy was taken during the surgery, immediately frozen in liquid nitrogen and stored at −80°C until further use. The phenotypic characterisation of the cohort has been performed as described previously (Kloting *et al*, [2010](#emmm201505801-bib-0042){ref-type="ref"}). Serum samples and liver biopsies were taken between 8 am and 10 am after an overnight fast. The study was approved by the local ethics committee of the University of Leipzig, Germany (363‐10‐13122010 and 017‐12‐230112). All patients gave preoperative written informed consent for the use of their samples.

Blood metabolites & hormones {#emmm201505801-sec-0014}
----------------------------

Blood glucose levels were determined using an automatic glucose monitor (One Touch, LifeScan). In addition, commercially available kits were used to measure serum non‐esterified fatty acids (NEFA; NEFA‐HR, Wako), glycerol/triglyceride (TG; TR‐0100; Sigma‐Aldrich), ketone bodies (KB; Autokit 3‐HB, Wako), cholesterol (CH200, Randox) and insulin (80‐INSMS‐E01, Alpco) essentially according to manufacturer\'s instructions. All samples were loaded in order to fit within the assay range of the reagents supplied. Acylcarnitines were determined in serum by electrospray ionisation tandem mass spectrometry (ESI‐MS/MS) according to a modified method as previously described (Sauer *et al*, [2006](#emmm201505801-bib-0070){ref-type="ref"}), using a Quattro Ultima triple quadrupole mass spectrometer (Micromass, Manchester, UK) equipped with an electrospray ion source and a Micromass MassLynx data system.

Tissue metabolite extraction and assay {#emmm201505801-sec-0015}
--------------------------------------

For tissue lipid determinations, frozen tissue samples were pulverised, weighed and extracted. Lipid analyses were conducted according to established guidelines (Argmann *et al*, [2006](#emmm201505801-bib-0003){ref-type="ref"}) using glycerol/triglyceride (TR‐0100; Sigma‐Aldrich), NEFA (NEFA‐HR, Wako) and cholesterol (CH200, Randox) assay kits. For liver glycogen determination, \~50 mg of liver powder was carefully weighed and extracted in 30% KOH followed by 70% ethanol precipitation. Resuspended glycogen was digested with amyloglucosidase (A7095, Sigma‐Aldrich, DEU) and glycogen digests were then assayed using a glucose assay kit (GAHK20, Sigma‐Aldrich, DEU). Liver tissue long‐chain acyl‐CoA species were extracted (Golovko & Murphy, [2004](#emmm201505801-bib-0029){ref-type="ref"}) and measured using an enzymatic assay (Barber & Lands, [1971](#emmm201505801-bib-0007){ref-type="ref"}). Values were calculated as molar concentration per gram wet tissue.

*Ex vivo* long‐chain fatty acid metabolism {#emmm201505801-sec-0016}
------------------------------------------

These experiments were carried out on precision‐cut liver slices (de Graaf *et al*, [2010](#emmm201505801-bib-0030){ref-type="ref"}) according to established guidelines for long‐chain fatty acid (LCFA) metabolism experiments (Watt *et al*, [2012](#emmm201505801-bib-0078){ref-type="ref"}). In particular, liver slices were taken and prepared (in absence of Insulin and Dexamethasone) from fed or fasted mice and pre‐incubated in Williams media E containing 50 μg/ml gentamycin, 5% dialysed FBS, 5 mM [d]{.smallcaps}‐glucose, 0.3 mM pyruvate, 0.1 μM methyl‐linoleate and an amino acid mixture resembling the hepatic portal vein concentrations (Patti *et al*, [1998](#emmm201505801-bib-0063){ref-type="ref"}). After 1 h, slices were then incubated with the same media containing 0.5 mM carnitine and BSA‐conjugated palmitic acid (50 μM) plus BSA‐conjugated oleic and linoleic acid mix (150 μM; L9655, Sigma‐Aldrich), representing the major (i.e. 67%) LCFA species in blood serum (Masood *et al*, [2005](#emmm201505801-bib-0055){ref-type="ref"}) together with trace amounts of \[9,10‐^3^H(N)\]‐palmitic acid (ART0129; American Radiolabeled Chemicals, USA), to trace LCFA metabolism, and \[1‐^14^C\]‐R‐2‐bromopalmitic acid (ARC3623; American Radiolabeled Chemicals, USA), a non‐metabolisable palmitate analogue (Oakes *et al*, [1999](#emmm201505801-bib-0061){ref-type="ref"}) to trace LCFA uptake. Incubations were conducted for 3 h after which media was collected and slices were washed in ice‐cold PBS, spot‐dried and snap‐frozen in LN~2~. Liver slice samples were homogenised in Solvable^™^ (PerkinElmer, DEU) and media were extracted (twice) according to Folch method (Folch *et al*, [1957](#emmm201505801-bib-0026){ref-type="ref"}) in order to count only the aqueous ^3^H~2~O reflecting FA oxidation. Samples were then analysed by dual‐dpm counting (Packard 2200CA Tri‐Carb Liquid Scintillation analyzer; Packard Instruments, USA) using multi‐purpose scintillant (Rotiszint^®^ eco plus, Carl‐Roth, DEU), and LCFA metabolism was calculated based upon the media tracer:tracee ratio (dpm/mol). Non‐oxidative LCFA disposal (NOFAD) rate was calculated as the difference between LCFA uptake and oxidation rates. In addition, liver slices from the same mice were allowed to incubate in media described above without glucose but with (BSA‐NEFA) or without (fatty acid‐free BSA vehicle) for 18 h and glucose concentration of the media was measured (GAHK20, Sigma‐Aldrich, DEU) and subsequently glucose production rate was calculated.

Plasmids, RNA interference and recombinant viruses {#emmm201505801-sec-0017}
--------------------------------------------------

AAV encoding control or specific miRNAs under the control of a hepatocyte‐specific promoter were established, purified and tittered as described previously (Graham *et al*, [2008](#emmm201505801-bib-0031){ref-type="ref"}; Rose *et al*, [2011](#emmm201505801-bib-0067){ref-type="ref"}). For miRNA experiments, oligonucleotides targeting mouse GADD45β (5′‐ GGCGGCCAAACTGATGAATGT ‐3′) and non‐specific oligonucleotides (5′‐AAATGTACTGCGCGTGGAGAC‐3′) were cloned into pcDNA6.2‐GW/EmGFP‐miR \["BLOCK‐iT^™^ PolII miR RNAi Expression Vector Kit" (Invitrogen, Darmstadt, DEU)\]. For the overexpression of GADD45β in the murine liver AD virus were produced. Therefore, mGadd45b cDNA (GenBank: BC023815.1; Source Bioscience, UK) was subcloned into pENTR‐FLAG vector and subsequently recombined with the pAD/BLOCK‐IT^™^ DEST vector (Invitrogen, DEU). Linearised plasmid was subsequently transfected into HEK293A cells to amplify viruses, and these were subsequently purified were purified by the caesium chloride method and dialysed against phosphate‐buffered saline buffer containing 10% glycerol prior to animal injection.

Tissue RNA/protein extraction and analysis {#emmm201505801-sec-0018}
------------------------------------------

Liver cell fractionation was performed using a simplified method adapted from Jiang and colleagues (Liu *et al*, [2011](#emmm201505801-bib-0052){ref-type="ref"}). Liver organelle fractionation was conducted via density‐based separation (Cox & Emili, [2006](#emmm201505801-bib-0021){ref-type="ref"}). RNA was extracted from tissues using Qiazol and cDNA synthesised using the First Strand cDNA synthesis kit (Fermentas, DEU). Quantitative PCR was conducted using Taqman master mix and Taqman primer‐probe assays (Life Technologies, DEU). Tissue protein extraction and immunoblotting was performed using standard methods using GADD45β (sc‐8776), FATP2 (sc‐161311), FABP1 (sc‐50380), HNF4a (sc‐6556), BCKDE1A (sc‐67200), NTCP (sc‐98485) and ARG1 (sc‐21050) (Santa‐Cruz Biotechnology, DEU); LC3B (2275), pT39‐S6K1 (9205), p‐ERK (9101), p‐p38 (9211), p‐eIF2a (9721) and GRP78 (3183) (Cell Signaling Technologies, USA); CD36 (AF2519, RnD Systems, USA); and the housekeeping protein VCP (ab11433, Abcam, UK) antibodies. Immunoprecipitation was conducted using anti‐FLAG (A2220, Sigma‐Aldrich, DEU) and anti‐HA (A2095, Sigma‐Aldrich, DEU) agarose from tissue lysates using standard protocols.

Study design criteria and statistical analyses {#emmm201505801-sec-0019}
----------------------------------------------

Based upon preliminary data showing the expected effect size of major outcome variables, a power analysis was conducted in order to determine the minimal number of animals to be used for each experiment. For genotype difference studies, offspring mice from Het × Het breedings were initially randomised to each experiment group. Afterwards, counterbalancing was done in order to realise equal sample sizes per experimental group. When conducting studies, the investigators were aware of which mouse was in which experimental group due to prior genotyping and allocation. However, the technical assistants involved in the studies were blinded.

Statistical analyses were performed using *t*‐tests (two‐sided), or 2‐way analysis of variance (ANOVA) with or without repeated measures, where appropriate, with Holm--Sidak‐adjusted post‐tests. Nonparametric tests (e.g. Mann--Whitney--Wilcoxon) were conducted when data were not normally distributed. Correlation was determined using Spearman\'s correlation coefficient. All analyses were carried out with SigmaPlot v.12 software (Systat Software GmbH, DEU).
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###### The paper explained

Problem {#emmm201505801-sec-0024}
-------

A hallmark of obesity‐driven T2D is insulin resistance, and thus "insulin sensitisation" has been an attractive strategy for treatment. However, insulin resistance likely represents a physiological feedback mechanism to actually retard the development of obesity‐driven complications. Thus, alternative strategies are warranted, such as mild and intermittent activation of stress‐responsive pathways that are pro‐adaptive.

Results {#emmm201505801-sec-0025}
-------

Here, we show that "growth arrest and DNA damage‐inducible" GADD45β as a dysregulated gene transcript during fasting in several models of metabolic dysfunction including ageing, obesity/pre‐diabetes and type 2 diabetes, in both mice and humans. Using whole‐body knockout mice as well as liver/hepatocyte‐specific gain‐ and loss‐of‐function strategies, we revealed a role for liver GADD45β in the coordination of liver fatty acid uptake, through cytoplasmic retention of FABP1, ultimately impacting obesity‐driven hyperglycaemia.

Impact {#emmm201505801-sec-0026}
------

We identified liver GADD45β as a novel regulator of systemic and hepatic lipid metabolism. Our findings demonstrate the importance of fasting hepatic lipid metabolism in systemic metabolic control and provide insight into the development of new therapies for metabolic dysfunction.
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